Marijuana Stocks To Watch In The 3rd Week Of January

Right now marijuana stocks in 2022 have shown some progress. Now we are not talking major runs or anything like that. But coming off of a year-long downtrend the start of 2022 has been fair so far. In the first 2 weeks of the year, the sector was able to see a small bit of upward consistency. Some feel this initial rise in trading was due to the excitement of starting a new year. Yet halfway through the first week of 2022 most cannabis stocks were dealing with some pullback. During the second week of January, the same pattern occurred as the first.

Trilogene Seeds reports the “THC Null” cultivar simply “cannot make THC.”

A Colorado-based company claims it may have the solution for ensuring hemp does not run afoul of U.S. requirements related to THC: make sure the cultivar contains none of the psychoactive compound.

Hemp — which offers promise as a windfall for CBD production — needs to adhere to certain rules to be considered hemp at all.

The so-called 2018 Farm Bill, which was signed into law on Dec. 20 of that year, demands that hemp contain no more than 0.3 per cent THC “on a dry weight basis,” notes a fact sheet from the U.S. Food and Drug Administration.

As the legal marijuana industry gains steam, Trulieve Cannabis, Columbia Care, and GrowGeneration are well-positioned for success.

It started as a small medical cannabis company in Florida. Now, it's the dominant player in its home state, where it operates 112 dispensaries. Staying focused on its core market helped the company grow its revenue and profits without overburdening its balance sheet. This strategy will also give it a competitive moat once Florida legalizes adult-use recreational cannabis, which experts predict could happen this year.

Meanwhile, Trulieve has slowly expanded into new markets; it now operates 159 stores nationally. 

In November, taxes for recreational marijuana sales in Arizona totaled around $5.05 million, slightly above medical cannabis tax, which amounted to $5.03 million.

Arizona continues to smash cannabis sales records, with yet another milestone of over $1.23 billion of marijuana products sold during the first 11 months of 2021, Arizona Mirror writes.

After soaring to record highs in October to nearly $58 million, adult-use recreational cannabis sales hit a new peak in November by surpassing $60 million for the first time. On the medical side, after reaching $73 million in March and April, sales fluctuated throughout the year.

Investing In Marijuana Stocks Right Now Could Be The Thing To Do In 2022

Some marijuana stocks are starting to see a slight increase in trading. Now, this is based on the recent momentum since the start of the new year. This past year the sector was faced with a lack of upward consistency. Mainly due to federal cannabis reform failing to pass. When that happened many thought the sector would not reach its full potential. Yet on a state level, many pure-play and MSO cannabis companies were able to flourish. With that form of progress, it was all outside of the market. Yet with fear and caution for those invested this outside progress did very little inside of the market. Right now in the sector, there are more volatile spikes.

When Louisiana's first legal smokable medical marijuana was made available on Jan. 1, patients like Corbet King of Wisner were excited about the product that they believed would be a more affordable option than tinctures, oils and edibles.

After all, affordability was one of the key selling points when the Legislature passed a bill last year to add the plant's unprocessed flower to the products that Louisiana's two legal growers and nine regional pharmacies could offer to patients.

But when King and other patients arrived at their pharmacies they were surprised to find the flower product in some cases was just as costly or even more expensive, depending on the pharmacy.

An effort by state regulators to rein in sale of intoxicating cannabis that can be produced with materials outside their authority has some major business interests crying foul.

The Washington Liquor and Cannabis Board has requested a change in the law that would explicitly permit it to prohibit the sale of intoxicating materials derived from hemp. The request comes on the heels of rulemaking started in earnest by the board last year after it was discovered that some of the state’s retailers were selling products including “delta-8 tetrahydrocannabinol (THC),” an intoxicant chemically similar to delta-9 THC found in adult marijuana plants, that had been produced from hemp, which was made federally legal following passage of the 2018 farm bill.

The company is by far the most significant REIT specializing in the marijuana industry.

The marijuana industry is not currently popular with investors, to put it mildly. That's having a knock-on effect with cannabis real estate investment trust (REIT) Innovative Industrial Properties. Despite being a consistently profitable company that doesn't actually grow or sell any weed itself, Innovative is being punished like its peers; its share price is down by over 15% so far this young year. A submerged stock price doesn't necessarily mean a company is a bargain, however. Let's explore whether Innovative stock is a good buy or a dangerous falling knife investors should avoid.

While federal law on a person’s past use of marijuana remains relevant, it is not determinative to decisions on eligibility for access to classified information or eligibility to hold a sensitive position.

For years, marijuana use has been — and still is — a red flag on a security clearance review. However, the sentiment seems to be changing, as more states move to legalize the plant, Marijuana Moment writes. Avril Haines, director of national intelligence (DNI), says that security clearance applicants who have used cannabis should not be instantly rejected when applying for a federal job. This internal notice, distributed to nearly 100 agencies in late December, builds upon guidance previously approved under the Obama administration.

Holief™ is proud to introduce a new line of women's wellness products that reduce the symptoms of PMS and menstrual cramping. 80% of women suffer from painful periods and we believe it is time for that discomfort to end. Holief's plant-based products include naturally grown hemp extract products, which are effective in targeting the physical, mental, and emotional symptoms of the menstruation cycle.

The cannabis stock sector is booming, with legalization and decriminalization of marijuana in the United States and abroad rapidly expanding. Investors want to know more about the cannabis investment opportunities from industry-leading experts. Today, we chatted with Serge Chistov, Chief Financial Partner with Honest Marijuana Company. Honest Marijuana Company is an eco-conscious cannabis growery. Serge has shared his expert insight on cannabis-related topics from financing to trends and product development, political environment and more with many high profile publications. He also has a background as a stockbroker and in wealth management services.

Schaeffer's: What opportunities does Honest Marijuana Company see for the cannabis industry as a whole?

What's in store for the new year and future of weed.

The U.S. cannabis market continues to boom to little surprise, but some experts caution that growth may decline in 2022.

With U.S. sales topping $37.4 billion in 2021, according to a Prohibition Partners' report, most see the new year as another success for pot. Still, regulations on federal and local levels could kneecap America's full potential.

Another Strong Year Expected, But Growth Could Slow: Sources across the board told Benzinga that they agreed with the optimistic projection for 2022.

Top Pot Stocks For Your Long Term Portfolio

Are you looking for top marijuana stocks while the cannabis sector is down? For almost a year the best cannabis stocks have been experiencing declines with most setting new lows in the last 2 months. For the most part, these declines can be attributed mostly to delays with federal cannabis reform in the US. As these delays continue the cannabis sector is pricing in 2022 without federal legalization or reform. In recent weeks one of the best performing parts of the cannabis sector has also experienced significant declines.

NutraLife Biosciences Inc. (OTC: NLBS) announces a feature article released by CFN Enterprises Inc. (OTCQB: CNFN), owner and operator of CFN Media, covering NutraLife’s rapidly growing expansion plans.

CBD has become one of the fastest-growing wellness products globally, reaching more than $11 billion in global sales last year. According to Market Data Forecast, these sales will continue to grow at a 22.2% annual pace to nearly $31 billion by 2026. As a result, companies building an early presence in the industry could be in a great position to profit.

More than a year after voters approved legalizing marijuana for recreational use in Montana, anyone older than 21 can now walk into a dispensary and buy cannabis. That has medical marijuana user Joylynn Mane Wright worried.

Wright lives in Prairie County, the state’s fifth-least-populated county, with nearly 1,100 people. She already drives about 35 minutes to get to the marijuana dispensary nearest her home, which is 2½ hours northeast of Billings. And now she wonders how much more difficult it will be to get the cannabis she uses to relieve the chronic pain she developed after a 2017 spinal surgery.

“I’m really worried about supplies and what it’s going to cost,” she said.

‘Not in my backyard,’ towns say

Around half of New York cities and towns don’t want marijuana dispensaries or consumption lounges, a cautionary signal for companies hoping to do business in the Empire State.

New York is expected to start recreational marijuana sales in the next year or so, likely becoming the second-biggest market after California, with around $4.2 billion in projected sales. Yet when given a Dec. 31 deadline to opt out of participating, 47% of the state’s 1,521 municipalities opted out of having dispensaries and 54% opted out of having consumption sites, according to data compiled by the Rockefeller Institute of Government as of Jan. 7.

As the cannabis industry expands, Michigan can expect greater tax revenue. Since 2019, the state has collected about $271 million in adult-use marijuana tax revenue, a website called The Center Square reports:  In March 2021, the Michigan Treasury described what adult-use cannabis taxes collected in fiscal year 2020 will fund:

“Aside from the nearly $10 million in disbursements to municipalities and counties, around $11.6 million will be sent to the School Aid Fund for K-12 education and another $11.6 million to the Michigan Transportation Fund, upon appropriation. The remaining $12.5 million amount will be used toward start-up and administrative costs.”

This high-growth duo could deliver jaw-dropping returns over the next three years.

Since the end of the Great Recession in 2009, growth stocks have been a powerful force on Wall Street. Historically low lending rates and the Federal Reserve's easy money policies have allowed fast-paced companies to hire, innovate, acquire, and invest in their businesses.

Even with the Fed hinting at raising rates to control runaway inflation, these dynamics are unlikely to change to a large degree anytime soon, which makes growth stocks still a good bet to continue to outperform.

The Oregon Liquor and Cannabis Commission has spent the last 18 months crafting new rules to improve the state’s cannabis industry.

The OLCC announced in a December 28 press release that it would be implementing new cannabis rules that will take effect between 2022 and 2023. Steve Marks, OLCC executive director, addressed the need for these changes, expressing the desired outcome after the changes go live. 

“These rules try to balance a number of different concerns—consumer health and safety, interests of small and large operators in our industry and public safety concerns around loopholes in the Federal Farm Bill of 2018, and the illicit farm production taking place in Oregon,” Marks said. 

We've been making a noted effort to highlight the potential of psychedelics and cannabis as it pertains to the medical industry and the investing ecosystem.

Today, we chatted with Melanie Davis, COO &  Director of Managed Service of The People's Ecosystem. Davis has decades of experience in the cannabis industry with extraordinary expertise in partnering, building, and growing businesses in the cannabis space. The People's Ecosystem is an organization focused on providing cannabis education, services and products while elevating resources and capital for minority canna-business owners. 

Schaeffer's: What opportunities does The People's Ecosystem see for the cannabis industry as a whole?